FY2025 Earnings Estimate for OLMA Issued By Lifesci Capital

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Olema Pharmaceuticals in a research note issued on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($2.12) for the year. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01).

Several other brokerages have also commented on OLMA. JPMorgan Chase & Co. dropped their price objective on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Trading Down 12.0 %

Shares of OLMA opened at $10.10 on Friday. Olema Pharmaceuticals has a 12 month low of $8.51 and a 12 month high of $17.23. The stock’s 50 day moving average is $12.05 and its two-hundred day moving average is $11.96. The firm has a market cap of $578.73 million, a P/E ratio of -4.61 and a beta of 2.02.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Olema Pharmaceuticals by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock worth $132,000 after buying an additional 4,442 shares during the last quarter. Portland Investment Counsel Inc. purchased a new stake in Olema Pharmaceuticals in the third quarter valued at $143,000. Cubist Systematic Strategies LLC purchased a new stake in Olema Pharmaceuticals in the second quarter valued at $145,000. SG Americas Securities LLC purchased a new stake in Olema Pharmaceuticals in the third quarter valued at $156,000. Finally, Entropy Technologies LP purchased a new stake in Olema Pharmaceuticals in the first quarter valued at $161,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.